{"product_id":"tevapharm-business-model-canvas","title":"Teva Pharmaceutical Industries Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva's Business Model: A Strategic Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Teva Pharmaceutical Industries's business model. This in-depth Business Model Canvas reveals how the company drives value through its diverse product portfolio and global reach, captures market share with its generics and specialty medicines, and stays ahead in a competitive landscape by focusing on innovation and operational efficiency. Ideal for entrepreneurs, consultants, and investors looking for actionable insights into a leading pharmaceutical giant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances for Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries actively pursues strategic alliances with universities, research institutions, and fellow pharmaceutical companies. These collaborations are crucial for accelerating drug discovery and development, a core tenet of their Pivot to Growth strategy.  For instance, in 2024, Teva continued to foster these relationships to access external scientific expertise and innovative solutions for their internal research and development pipeline, aiming to reduce development timelines and enhance the success probability of new drug candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Development and Commercialization Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries actively seeks key partnerships to bolster its biosimilar business. These alliances are crucial for Teva’s ambition to grow in the biosimilar market, covering development, manufacturing, and bringing these complex medicines to patients.\u003c\/p\u003e\n\u003cp\u003eA prime example is Teva's extended collaboration with mAbxience. This partnership focuses on oncology biosimilar candidates. Under this agreement, mAbxience is responsible for the intricate development and manufacturing processes, while Teva takes the lead on navigating regulatory approvals and the subsequent commercialization efforts.\u003c\/p\u003e\n\u003cp\u003eThis strategic approach allows Teva to leverage external expertise in biosimilar production while concentrating its resources on market access and patient reach. As of recent reports, biosimilars represent a significant growth area for Teva, with ongoing investments in expanding its pipeline and partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI Business Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries continues to leverage its API business through strategic collaborations, even as it plans to divest this segment. For the entirety of 2025, Teva expects a full year contribution from Teva API, underscoring the importance of these operational partnerships during its portfolio optimization. This approach ensures continued access to essential components while Teva refines its global manufacturing and business focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Ecosystem Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries actively partners with hospitals and health maintenance organizations (HMOs). These collaborations are designed to enhance patient access to Teva's diverse range of medicines and comprehensive healthcare solutions.  In 2024, Teva continued to focus on these relationships to better understand evolving market demands and to streamline the delivery of its pharmaceutical products directly to patients.\u003c\/p\u003e\n\u003cp\u003eThese strategic alliances are fundamental to Teva's operational strategy, providing invaluable insights into real-world healthcare needs and patient populations. By working closely with healthcare providers, Teva can ensure its medications reach those who need them most, efficiently and effectively.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospital Networks:\u003c\/strong\u003e Collaborations with major hospital systems to facilitate medication access and patient support programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHealth Maintenance Organizations (HMOs):\u003c\/strong\u003e Partnerships with HMOs to integrate Teva's generics and specialty medicines into their formularies and patient care pathways.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Insight:\u003c\/strong\u003e Gaining direct feedback from these organizations on patient needs, treatment adherence challenges, and market trends.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Efficiency:\u003c\/strong\u003e Optimizing the supply chain and delivery mechanisms through these key healthcare stakeholders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and AI-focused Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries actively pursues technology and AI-focused partnerships to drive innovation in drug discovery and development. A prime example is its involvement in AION Labs, a significant alliance that unites major pharmaceutical companies, Amazon, and the Israel Biotech Fund.\u003c\/p\u003e\n\u003cp\u003eThis collaboration is specifically designed to foster and support startups that harness the power of artificial intelligence within the critical areas of drug discovery and development. Such strategic alliances underscore Teva's commitment to a forward-thinking approach, aiming to accelerate the identification and creation of novel therapeutic solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAION Labs: \u003c\/strong\u003e A collaboration featuring Teva, Amazon, and the Israel Biotech Fund.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAI in Drug Discovery: \u003c\/strong\u003e Focuses on startups leveraging AI for early-stage drug development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Acceleration: \u003c\/strong\u003e Aims to speed up the process of bringing new medicines to market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships Drive R\u0026amp;D and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva's key partnerships extend to academic institutions and research organizations, crucial for advancing its R\u0026amp;D pipeline, particularly in oncology and biosimilars.  These collaborations, including those with universities for early-stage research, were actively pursued throughout 2024 to tap into external scientific expertise and accelerate the development of new therapies.  For example, Teva's ongoing engagement with various research bodies aims to identify novel drug targets and validate innovative treatment approaches.\u003c\/p\u003e\n\u003cp\u003eTeva also strategically partners with other pharmaceutical firms and biotech companies, especially in the biosimilar space. These alliances are vital for sharing development costs, accessing specialized manufacturing capabilities, and expanding market reach for complex biologic medicines.  In 2024, Teva continued to solidify these relationships to strengthen its position in the competitive biosimilar market, aiming to bring more affordable treatment options to patients.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Teva collaborates with technology firms and venture capital funds, such as its involvement in AION Labs, to leverage artificial intelligence and digital solutions in drug discovery. This focus on innovation partnerships is designed to streamline the R\u0026amp;D process and identify promising early-stage drug candidates more efficiently, reflecting a commitment to cutting-edge advancements in medicine development.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries' business model focuses on delivering affordable generic and specialty medicines to a broad customer base, leveraging its extensive manufacturing and distribution capabilities.\u003c\/p\u003e\n\u003cp\u003eThis model is designed to maximize market reach and profitability through efficient production, strategic partnerships, and a robust product pipeline, reflecting its operational strengths and market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries' Business Model Canvas acts as a pain point reliever by streamlining complex supply chains and regulatory navigation, offering a clear, actionable roadmap for efficient drug development and distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries dedicates substantial resources to research and development, focusing on innovative treatments for central nervous system disorders, respiratory illnesses, and cancer. This commitment is crucial for expanding its product portfolio and addressing unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eA key activity involves advancing clinical trials for promising new drug candidates. For instance, duvakitug is progressing through development, representing Teva's focus on specialty medicines. The company also actively pursues biosimilar development, aiming to bring more affordable alternatives to market.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Teva reported R\u0026amp;D expenses of approximately $1.7 billion, underscoring its significant investment in future growth and innovation. This expenditure supports the development of both novel specialty drugs and complex generics, including biosimilars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries maintains a vast global network of manufacturing facilities, emphasizing stringent quality control and leveraging economies of scale to produce its diverse pharmaceutical products efficiently. This extensive infrastructure is crucial for meeting worldwide demand and ensuring consistent product availability.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Teva continued its strategic focus on optimizing its manufacturing footprint as a cornerstone of its 'Pivot to Growth' strategy. This involves carefully managing its production sites to align with market needs and support efficient capital deployment, aiming to enhance operational agility and cost-effectiveness across its global operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Drug Development and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva's core activity revolves around developing, manufacturing, and marketing a broad range of affordable generic drugs. This is crucial for increasing access to essential medicines worldwide.\u003c\/p\u003e\n\u003cp\u003eA significant part of this involves being among the first to launch generic versions of widely used brand-name medications. In 2023, Teva reported approximately $17.0 billion in total revenue, with generics forming a substantial portion of this figure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Medicine Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries focuses on the commercialization of its innovative specialty medicines. This involves significant investment in marketing and sales to establish market presence and drive adoption in targeted therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eKey activities include building specialized sales forces and engaging in direct-to-physician and direct-to-patient campaigns. For instance, AUSTEDO, used for tardive dyskinesia and Huntington's disease, and AJOVY, for migraine prevention, are central to this strategy. These efforts aim to capture market share and establish Teva as a leader in these specific medical fields.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDriving growth through specialty product commercialization\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarketing and sales efforts for AUSTEDO and AJOVY\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGaining market share in neurology and immunology\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Optimization and Divestitures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries is strategically refining its business by divesting non-core assets. This includes the sale of its Active Pharmaceutical Ingredient (API) business and a specific venture in Japan. These moves are designed to sharpen Teva's focus on its key growth areas and bolster its financial health.\u003c\/p\u003e\n\u003cp\u003eBy shedding these less central operations, Teva aims to streamline its structure and allocate resources more effectively. This portfolio optimization is a critical component of its long-term strategy to improve profitability and market position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Optimization:\u003c\/strong\u003e Teva's divestitures aim to concentrate on high-growth segments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDivestiture Examples:\u003c\/strong\u003e The sale of its API business and a Japanese venture are key examples.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Rationale:\u003c\/strong\u003e These actions support a focus on core growth engines and financial stability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDriving Pharma Innovation and Strategic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries' key activities center on robust research and development, aiming to innovate treatments for complex conditions like CNS disorders and cancer. This includes advancing promising drug candidates through clinical trials, such as duvakitug, and expanding its biosimilar offerings to improve medication accessibility.\u003c\/p\u003e\n\u003cp\u003eThe company also focuses on efficient global manufacturing, ensuring high-quality production of its diverse product lines. In 2024, Teva continued optimizing its manufacturing network as part of its growth strategy, enhancing operational agility and cost-effectiveness.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Teva drives revenue by commercializing its specialty medicines, investing heavily in marketing and sales for key products like AUSTEDO and AJOVY. This strategy aims to build market share in targeted therapeutic areas, particularly neurology and immunology.\u003c\/p\u003e\n\u003cp\u003ePortfolio optimization is another critical activity, evidenced by Teva's divestment of non-core assets like its API business. This strategic move allows for a sharper focus on core growth engines and improved financial health.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2023\/2024 Data\/Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDeveloping new treatments and biosimilars\u003c\/td\u003e\n\u003ctd\u003e$1.7 billion R\u0026amp;D expenses in 2023; focus on CNS, respiratory, cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eProducing diverse pharmaceutical products globally\u003c\/td\u003e\n\u003ctd\u003eOptimizing manufacturing footprint in 2024 for efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Product Commercialization\u003c\/td\u003e\n\u003ctd\u003eMarketing and sales of innovative medicines\u003c\/td\u003e\n\u003ctd\u003eFocus on AUSTEDO and AJOVY; gaining market share in neurology\/immunology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio Optimization\u003c\/td\u003e\n\u003ctd\u003eDivesting non-core assets\u003c\/td\u003e\n\u003ctd\u003eSale of API business and Japanese venture to sharpen focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas for Teva Pharmaceutical Industries you're previewing is the actual, comprehensive document you'll receive upon purchase. This isn't a sample; it's a direct snapshot of the complete analysis, detailing Teva's key partners, activities, resources, value propositions, customer relationships, channels, customer segments, cost structure, and revenue streams. You'll gain immediate access to this exact, ready-to-use document, allowing you to fully understand and leverage Teva's strategic framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674772226425,"sku":"tevapharm-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/tevapharm-business-model-canvas.png?v=1755795119","url":"https:\/\/portersfiveforce.com\/products\/tevapharm-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}